Anavex Life Sciences Corp (AVXL)

[falconer66a]

The prophylaxis factor.

Might the 3-71 trial be designed for these younger folks and their responses, given 3-71's impact, which allows TGD et al time to determine how well an older group might do with 3-71 at a later date?

This is a big unknown; of profound significance. We have early, incomplete (but valid) data showing that Anavex 2-73 (blarcamesine) can really treat at least three central nervous system diseases: Rett syndrome, Parkinson's disease dementia, and Alzheimer's. All of this will be further authenticated with new clinical evidence to appear.

I've mentioned this before. Except for Rett symptoms, caused by an operating genetic defect almost at birth, the other CNS diseases being treated with blarcamesine have general geriatric onset; they appear in the later stages of life. In youth and middle age, only an exceptional few, with particular genetic anomalies, express symptoms. Kids and middle-aged adults are symptom-free.

Therefore, what is the potential of any of the (presently two) Anavex sigma-1 receptor agonists to not only turn down or turn off CNS disease symptoms after they appear (in older age), but actually prevent their occurrence with earlier, pre-symptomatic administration. The concept of prophylaxis.

To me, prophylactic administration of either of the Anavex drugs, before any symptoms actually appear, makes sense. Perhaps blarcamesine, at its much higher dosages (in milligrams) tends, over longer dosing periods to produce adverse events, compared to Anavex 3-71 (dosed in micrograms).

Again, all of this can be checked with murine (lab rodent) testing. The genes for human CNS diseases can be inserted into the genomes of rats. Then, at varying doses and rat ages the Anavex drugs can be tested. Anavex has surely done those studies; has some good indications of how all of this will play out in real humans.

But, to check this in people costs millions of dollars. Anavex is prudently using its dollars to support human tests for things they know will work in people; the three human clinical trials drawing to an end. After that, blarcamesine will be approved for sale and use. The company will then have ample dollars to initiate new human clinical trials, this time with Anavex 3-71.

Note. I've preciously stated it will take five to ten years for the Anavex story to be written, with both new drugs and new clinical trials against new diseases. Time and dollars. Trying to parse the Anavex future in financial quarters (3-month periods) won't work.